TARSONS NSE filing

Tarsons Products Q2 FY27: Standalone Revenue Surges 25%, Consolidated Up 21%

The RealCase readHigh impact Positive

Tarsons Products reported record revenues in Q2 FY27, with standalone revenue up 25% and consolidated revenue up 21% year-on-year. Standalone Q2 revenue surpassed ₹100 crore for the first time. Export revenue saw a significant 37% growth. New facilities are nearing full operational capacity, with cell culture line commissioning expected in H2 FY27.

Why it matters

The announcement details significant revenue growth, record financial performance, and progress on strategic expansion initiatives, indicating a positive trajectory for the company's future performance.

The market read

The company reported record revenues, strong year-on-year growth in both standalone and consolidated figures, and significant export growth. Despite margin pressures from raw material costs, the company effectively mitigated the impact through volume growth and operational efficiencies.

Tarsons Products Limited announced a robust financial performance for the quarter and half-year ended September 30, 2026. The company achieved its highest-ever quarterly and half-yearly revenue. Standalone revenue grew by 25% in Q2 FY27 and 23% in H1 FY27 year-on-year, with standalone Q2 revenue crossing the ₹100 crore mark for the first time.

Consolidated revenue for H1 FY27 stood at ₹233.9 crore, a 21% year-on-year growth. Domestic revenue grew by 19% and export revenue by a strong 37% in Q2 FY27. The company's new facilities are in the final phase of expansion, with most capacities commissioned. Commissioning of cell culture lines at Panchla is expected in the second half of the year.

Despite significant gross margin pressure due to a 30-50% surge in crude-linked raw material prices, the company mitigated the impact at the EBITDA level through volume increases and operating leverage. The management expressed confidence in sustaining demand, driven by existing product portfolios and an uptick in inquiries, particularly from the pharma and healthcare sectors. The company is also focused on expanding its global presence, with standalone export business growing 37% in the quarter.

Filing to action

What to do with a filing like this

Tarsons Products Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Tarsons Products Limited. Read the original for the full detail.

View original filing